Roy M Fleischmann

59PUBLICATIONS
82CO-AUTHORS
OrthopticsOptical technologyInnate immunityRegenerative medicine (incl. stem cells)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (59)

|Jun 24, 2026
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study.

|May 16, 2026
Olokizumab Improves Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis up to 106 Weeks (Results from the Open-Label Extension of Phase III Randomized Clinical Trials).

|Feb 24, 2026
Baseline Interleukin-10 Levels as a Predictive Biomarker for Achieving Clinical Response With Abatacept in Patients Who Were Disease-Modifying Antirheumatic Drug Naive and Anti-Citrullinated Protein Antibody Positive With Early Rheumatoid Arthritis.

Jinqi Liu, Yicong Li, Kai Fu

|Jan 21, 2026
Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis.

Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka

|Jun 03, 2025
Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease.

|Feb 21, 2025
Have we found a true disease-modifying osteoarthritis drug (DMOAD) or is there still much work to be done?

Roy Fleischmann

Pageof 10

Frequent Collaborators

9 joint publications

Yoshiya Tanaka

5 joint publications

Désirée van der Heijde

5 joint publications

Paul Emery

4 joint publications

Peter Taylor